Restriction Requirement

The Restriction Requirement mailed April 16, 2010, outlined twelve (12) groups of claims as follows:

Group I, claims 2, 4-6, 9-10, 13, 15 and 20 (in part), drawn to an isolated nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, an expression vector comprising said isolated nucleic acid molecule and a regulatory nucleic acid controlling the expression of the polypeptide encoded by said isolated nucleic acid molecule, a host cell genetically engineered to contain said expression vector, a transgenic non-human animal comprising said isolated nucleic acid, wherein the expression of said isolated nucleic acid molecule according to the SEQ ID NO's recited in Claim 1 is upregulated, and a pharmaceutical composition comprising said isolated nucleic acid;

Group II, claims 2-3, 5, 9-10, and 20 (in part), drawn to an siRNA molecule targeted to an isolated nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, a host cell genetically engineered to contain said siRNA molecule, a non-human transgenic animal genetically engineered to contain said siNRA molecule in which the expression of said isolated nucleic acid molecule according to the SEQ ID NO's recited in Claim 1 is downregulated or absent, and a pharmaceutical composition comprising said siRNA molecule;

Group III, claims 12 and 16, drawn to an isolated polypeptide comprising an amino acid sequence substantially corresponding to one of the SEQ ID NO's recited in Claim 12;

Group IV, claim 8, drawn to an antibody with specific reactivity to a nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1;

Group V, claim 14, drawn to an antibody specifically reactive with a polypeptide comprising an amino acid sequence substantially corresponding to one of the SEQ ID NO's recited in Claim 12;

Group VI claims 7 and 19 (in part), drawn to a method of treating an angiogenesis-related condition comprising the step of administering an expression vector encoding a polypeptide encoded by a nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, wherein vasculogensis or angiogenesis is enhanced or increased;

Group VII, claims 7 and 19 (in part), drawn to a method of treating an angiogenesis-related condition comprising the step of administering an expression vector encoding a polypeptide encoded by a nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, wherein vasculogenesis or angiogenesis is inhibited or decreased;

Group VIII, claims 19 (in part), drawn to a method of treating an angiogenesis-related condition comprising the step of administering an expression vector encoding an siRNA targeted to a nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, wherein vasculogenesis or angiogenesis is enhanced or increased;

Group IX, claims 19 (in part), drawn to a method of treating an angiogenesis-related condition comprising the step of administering an expression vector encoding an siRNA targeted to a nucleic acid molecule according to one of the SEQ ID NO's recited in Claim 1, wherein vasculogenesis or angiogenesis is inhibited or decreased;

Group X, claims 11, 17 and 21, drawn to a method of affecting vasculogenesis or angiogenesis comprising administering a pharmaceutical composition comprising an isolated polypeptide comprising an amino acid sequence substantially corresponding to one of the SEQ ID NO's recited in Claim 12, wherein vasculogenesis or angiogenesis is enhanced or increased;

Group XI, claims 11, 17 and 21, drawn to a method of affecting vasculogenesis or angiogensis comprising administering a pharmaceutical composition comprising an isolated polypeptide comprising an amino acid sequence substantially corresponding to

one of the SEQ ID NO's recited in Claim 12, wherein vasculogenesis or angiogenesis is inhibited or decreased; and

Group XII, claim 18, drawn to a method of detecting an angiogenesis-related transcript in a cell, the method comprising contacting a biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence according to one of the SEQ ID NO's recited in Claim 18.

In response to the Restriction Requirement, Applicants herein elect without traverse **Group XI, Claims 11, 17, and 21,** drawn to a method of affecting vasculogenesis or angiogensis, and particularly to a method of decreasing vasculogenesis or angiogenesis in response to administration of a pharmaceutical composition comprising an isolated polypeptide comprising an amino acid sequence substantially corresponding to one of the SEQ ID NO's recited in Claim 12. Applicants submit that claims 11, 17, and 21 encompass the elected invention.

The Examiner also requested that the Applicants further elect a single nucleic acid subgroup and/or corresponding siRNA and/or corresponding polypeptide encoded by said nucleic acid subgroup selected from SEQ ID NOS (a) through (j) on page 6 of the Restriction Requirement.

In response, Applicants herein select sequence group (g), SEQ ID NO:34 and SEQ ID NO:36, as well as SEQ ID NO:35 and SEQ ID NO:37, which are polypeptides encoded by nucleic acid sequences SEQ ID NO:34 and SEQ ID NO:36, respectively.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

Mats Hellstrom et al.

Date: 12 MAY 2010

By Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508
Telephone:(203) 498-4400
Fax: (203) 782-2889

15169\3\2370832.1